Opendata, web and dolomites

SIROCO SIGNED

Sparing gene therapy for Inherited ROd COne dystrophies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SIROCO project word cloud

Explore the words cloud of the SIROCO project. It provides you a very rough idea of what is the project "SIROCO" about.

stopped    primarily    million    small    innovative    therapeutic    blindness    rdcvf    group    potentially    sahel    cone    supporting    young    raised    photoreceptor    leads    unnecessary    adults    people    therapy    disorders    models    genetic    corrective    licenses    solution    world    pathology    dry    believe    65    almost    clinical    subsequent    agreements    injected    disease    remaining    proof    photoreceptors    treatment    renamed    mutations    pigmentosa    ip    pursue    accessible    efficacy    sme    rod    treat    degeneration    first    single    team    ophthalmology    injection    rare    inherited    amd    vision    retinal    scientific    validation    progressive    advisory    neurotrophic    leveillard    evolution    option    exclusive    diffuse    patients    instrument    protection    forms    treating    2004    money    secured    degenerative    patents    mice    board    causes    retinitis    many    dysfunction    retina    saving    cones    gene    diseases    lasting    sparingvision    rp    tomorrow    finalize    repair    siroco    stop   

Project "SIROCO" data sheet

The following table provides information about the project.

Coordinator
SPARINGVISION 

Organization address
address: 55 RUE DE LYON
city: PARIS
postcode: 75012
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙529˙593 €
 EC max contribution 2˙470˙715 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SPARINGVISION FR (PARIS) coordinator 2˙470˙715.00

Map

 Project objective

Many believe that corrective ophthalmology gene therapy is the future for rare diseases such as retinitis pigmentosa (RP), a rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors. This degenerative disease causes blindness to young people and adults. But with this kind of therapy only treating 1 out of 65 mutations of the pathology, it means a small group of patents can be targeted. So, what do the remaining 2 million people have as on option? SparingVision have developed an innovative treatment that can stop the evolution of this blindness and we call it RdCVF. The first vision saving treatment of its kind. What makes it different is that in 2004, J Sahel and T Leveillard identified that in RP, the main factor that leads to blindness is a loss of RdCVF with is a neurotrophic factor for the cones (photoreceptor). This means that by a single injection under the retina SparingVision’ product can treat all the genetic forms of RP, potentially treat patients with dry AMD, and provide patients with long lasting efficacy. In SparingVision’ proof of concept the product was injected to mice models provided almost immediate protection and repair to the cones and the evolution to blindness is stopped. Behind this product is a very strong team, a world renamed scientific advisory board. The product development has been secured with strong IP, exclusive licenses agreements and pursue R&D with research collaboration agreements and raised money. So, tomorrow with the help of SME INSTRUMENT supporting the project SIROCO, SparingVision will be able to finalize the next steps of the clinical validation of an unique therapeutic approach and make the product finally accessible and being the solution to stop unnecessary blindness and other degenerative conditions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIROCO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIROCO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More